Economic TimesLean R·
The growing burden of cancer drugs
Six months ago, Surekha Panicker (name changed), a 65-year-old retired professional from Kerala, stared at her diagnosis in shock—stage-2 breast cancer. She had no family and limited savings. She went to an oncologist at a leading private hospital to figure out a treatment plan. They decided on immunotherapy, particularly Roche’s injection Phesgo, which would cost Rs 5 lakh for the first loading dose of a 1,200 mg vial and over Rs 2 lakh for subsequent doses. She was offered a “buy one, get one…
Read at Economic Times →
